Health CanadaGeneral Alert
Clinical management support: Known interference between Hemlibra® (emicizumab in...
Published: April 17, 2020Recall ID: 63310Category: generalCountry: Canada
Reason for Recall / Hazard
Product safety
Product Description & Identification
Clinical management support: Known interference between Hemlibra® (emicizumab injection) and lab assays used to diagnose coagulopathy / DIC caused by COVID-19 infection
Additional Source Details
| Field | Value |
|---|---|
| N I D | 63310 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/clinical-management-support-known-interference-between-hemlibrar-emicizumab-injection |
| Issue | Product safety |
| Title | Clinical management support: Known interference between Hemlibra® (emicizumab injection) and lab assays used to diagnose coagulopathy / DIC caused by COVID-19 infection |
| Archived | 0 |
| Category | Biologic or vaccine |
| Last updated | 2020-04-17 |
| Organization | Marketed health products |